港股异动 | 翰森制药(03692)午前涨超4% 阿美乐®获批第五项适应症辅助治疗研究登上《柳叶刀·肿瘤学》

智通财经01-13

智通财经APP获悉，翰森制药(03692)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐® (甲磺酸阿美替尼片)获中国国家药品监督管理局(“NMPA”)签发的药品注册证书，批准增加“阿美乐®联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子 21(L858R)置换突变...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603571361?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-13 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603571361","market":"sh","top_or_hot":-1,"title":"港股异动 | 翰森制药(03692)午前涨超4% 阿美乐®获批第五项适应症 辅助治疗研究登上《柳叶刀·肿瘤学》","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，翰森制药(03692)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐® (甲磺酸阿美替尼片)获中国国家药品监督管理局(“NMPA”)签发的药品注册证书，批准增加“阿美乐®联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子 21(L858R)置换突变...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392075.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 翰森制药(03692)午前涨超4% 阿美乐®获批第五项适应症 辅助治疗研究登上《柳叶刀·肿瘤学》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 翰森制药(03692)午前涨超4% 阿美乐®获批第五项适应症 辅助治疗研究登上《柳叶刀·肿瘤学》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 11:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1392075.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，翰森制药(03692)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐® (甲磺酸阿美替尼片)获中国国家药品监督管理局(“NMPA”)签发的药品注册证书，批准增加“阿美乐®联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子 21(L858R)置换突变...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392075.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1392075.html","article_id":"2603571361","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603571361","pubTimestamp":1768275406,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，翰森制药午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐 获中国国家药品监督管理局签发的药品注册证书，批准增加“阿美乐联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体外显子19缺失或外显子 21置换突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗”适应症。此为阿美乐获批的第五项适应症。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"Changes in Hong Kong stocks | Hansoh Pharmaceutical (03692) rose more than 4% before noon Amelo ® Approved for the fifth indication adjuvant treatment study, published in The Lancet Oncology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1.5},"content_text":"智通财经APP获悉，翰森制药(03692)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐® (甲磺酸阿美替尼片)获中国国家药品监督管理局(“NMPA”)签发的药品注册证书，批准增加“阿美乐®联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子 21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(“NSCLC”)成人患者的一线治疗”适应症。此为阿美乐®获批的第五项适应症。值得一提的是，据翰森制药官微消息，近日，国际顶级肿瘤学期刊《Lancet Oncology》(中文译名：《柳叶刀·肿瘤学》，影响因子：35.9)在线重磅发布了翰森制药创新药阿美乐®(甲磺酸阿美替尼片，110mg)用于EGFR突变非小细胞肺癌辅助治疗的最新研究结果。数据显示，阿美乐®能够显著改善完全切除的Ⅱ-ⅢB期EGFR突变NSCLC患者的无病生存期(DFS)，且安全性良好。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603571361","isCrawlerRequest":true}

港股异动 | 翰森制药(03692)午前涨超4% 阿美乐®获批第五项适应症 辅助治疗研究登上《柳叶刀·肿瘤学》

精彩评论

港股异动 | 翰森制药(03692)午前涨超4% 阿美乐®获批第五项适应症辅助治疗研究登上《柳叶刀·肿瘤学》